DDInter1042 DDInter1679
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006.
Sitagliptin {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Sitagliptin {u} (Compound) binds {v} (Gene) DPP4
Sitagliptin {u} (Compound) upregulates {v} (Gene) TSPAN8
Sitagliptin {u} (Compound) is included by {v} (Pharmacologic Class) Dipeptidyl Peptidase 4 Inhibitors
Sitagliptin {u} (Compound) downregulates {v} (Gene) CTSD
Sitagliptin {u} (Compound) causes {v} (Side Effect) Back pain
Sitagliptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Sitagliptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dulaglutide
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quetiapine
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Corticotropin
Sitagliptin (Compound) treats type 2 diabetes mellitus (Disease)
Sitagliptin (Compound) binds DPP4 (Gene)
Sitagliptin (Compound) upregulates TSPAN8 (Gene)
Sitagliptin (Compound) is included by Dipeptidyl Peptidase 4 Inhibitors (Pharmacologic Class)
Sitagliptin (Compound) downregulates CTSD (Gene)
Sitagliptin (Compound) causes Back pain (Side Effect)
Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin